Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.50 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.50 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29221029 | 0.91 | RIPK1 (0.51) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL29221006 | 0.91 | RIPK1 (0.51) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL29221022 | 0.88 | PRKAB2 (0.52) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL29221034 | 0.84 | PTPN1 (0.51) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL30954358 | 0.84 | PTPN1 (0.51) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL29221024 | 0.84 | PTPN1 (0.60) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL5429419 | 0.83 | PTPN1 (0.61) | PTPN1HTR7KDM4ERAB9A | |
| SCHEMBL5426730 | 0.83 | PTPN1 (0.54) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL29221075 | 0.81 | PTPN1 (0.54) | PTPN1HTR7ALDH1A1KDM4ETHRB | |
| SCHEMBL5423449 | 0.81 | KDM4E (0.57) | PTPN1HTR7ALDH1A1KDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | claimed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | claimed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | claimed |
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015813-A1 | Treatment of protein folding disorders | HSPA5, TTR, TUFM | PTPN1 4634/4885HTR7 1505/4885ALDH1A1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.